AI Analysis
AI-generated analysis. Always verify with the original filing.
Quantum BioPharma Ltd. announced the peer-reviewed publication of a double-blind, randomized, placebo-controlled clinical trial (NCT06505239) for unbuzzd, demonstrating statistically significant acceleration of alcohol metabolism (over 40% faster BAC reduction in 30 minutes), reduced intoxication symptoms, impairment, and hangover (67% headache reduction), with no side effects. The Company owns 19.86% of Unbuzzd Wellness Inc. (as of September 30, 2025) and receives 7% royalties on unbuzzd sales up to $250 million.
Key Takeaways
1unbuzzd reduced BAC over 40% faster within 30 minutes vs placebo, statistically significant in males and females.
2Statistically significant improvements in alertness, heart rate stabilization, reduced impairment, mental fatigue, and hangover symptoms (67% headache reduction at 4 hours).
3Publication in World Journal of Pharmaceutical and Medical Research (2026, volume 12, issue 3, pages 446-467).
4Quantum BioPharma retains 19.86% ownership in Unbuzzd Wellness Inc. (as of September 30, 2025) and 7% royalties on unbuzzd sales until $250 million, then 3% perpetuity.